↓ Skip to main content

A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory…

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, November 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy
2 policy sources

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
52 Mendeley
Title
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
Published in
Cancer Chemotherapy and Pharmacology, November 2012
DOI 10.1007/s00280-012-2027-3
Pubmed ID
Authors

Sun Jin Sym, Junshik Hong, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Yeon Ho Park, Woon Ki Lee, Min Chung, Hyung-Sik Kim, Se Hoon Park, Dong Bok Shin

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
Unknown 50 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 17%
Student > Ph. D. Student 6 12%
Other 5 10%
Student > Master 4 8%
Student > Doctoral Student 3 6%
Other 7 13%
Unknown 18 35%
Readers by discipline Count As %
Medicine and Dentistry 19 37%
Biochemistry, Genetics and Molecular Biology 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Agricultural and Biological Sciences 2 4%
Computer Science 2 4%
Other 5 10%
Unknown 18 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#4,972,158
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#244
of 2,501 outputs
Outputs of similar age
#50,476
of 282,068 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#3
of 26 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,068 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.